A new clinical trial is bringing hope to patients with advanced prostate cancer, particularly those with metastatic castration-resistant prostate cancer (mCRPC) harboring HRR genetic mutations. The global Phase 1/2 study,  is testing EIK1003 (IMP1734), a novel PARP1-selective inhibitor.Unlike existing PARP inhibitors that often cause significant blood-related side effects, EIK1003 aims to maintain strong antitumor effects while reducing toxicity, potentially offering a safer treatment option for patients with limited choices.
Prostate cancer remains a major health challenge, and mCRPC, which progresses despite hormone therapy, is particularly difficult to treat. Current therapies like olaparib and rucaparib, known as PARP inhibitors, are effective for patients with mutations in DNA repair genes like BRCA1/2 and ATM, but they target both PARP1 and PARP2, leading to side effects such as anemia and low white blood cell counts. These toxicities can force dose reductions or treatment breaks, limiting benefits. EIK1003, selectively targets PARP1, aiming to avoid PARP2-related toxicities. Preclinical studies showed it inhibits tumor growth, prompting its evaluation in humans.

Source.